MCM
CRVS icon

Manchester Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Manchester Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-215
Closed -$1K – 746
2020
Q3 		$1K Hold
215
– – ﹤0.01% 494
2020
Q2 		$1K Hold
215
– – ﹤0.01% 537
2020
Q1 		$0 Hold
215
– – ﹤0.01% 550
2019
Q4 		$1K Buy
+215
New +$752 ﹤0.01% 518

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Manchester Capital Management's CRVS Position: Q4 2020 in Review

Manchester Capital Management sold out of Corvus Pharmaceuticals (CRVS) in Q4 2020, closing a stake of 215 shares — an estimated $1K sold.

Manchester Capital Management first reported a position in CRVS in Q4 2019 and held it in 4 quarters. The position peaked at $1K in Q3 2020. 38 funds tracked by Wall St. Rank hold CRVS as of Q4 2020.

  • Manchester Capital Management reported no remaining Corvus Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Manchester Capital Management sold 215 Corvus Pharmaceuticals shares in Q4 2020, an estimated $1K.
  • Manchester Capital Management first reported a position in Corvus Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • Manchester Capital Management's Corvus Pharmaceuticals position peaked at $1K in Q3 2020.
  • 38 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2020.

Based on Manchester Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.